NCT06345066CompletedPhase 1
A Study of LY3841136 in Overweight and Obese Participants
A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants
Source: ClinicalTrials.gov · Last updated 15 Oct 2025
Brief summary (registry, in English)
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 28 Mar 2024
- Start date
- 3 Apr 2024
- Primary completion date
- 29 Sept 2025
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06345066
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 96
- From 3 Apr 2024 to the primary completion date, 29 Sept 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.
Other illness
- Have type 1 or type 2 diabetes mellitus
- Have a history or presence of psychiatric disorders
Other
- Have an abnormal 12-lead electrocardiogram (ECG)
- Have abnormal blood pressure and pulse rate
Who the study is looking for
- Male and female participants who are overtly healthy as determined by medical evaluation
- Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
- Have clinical laboratory test results within normal reference range
- Have venous access sufficient to allow for blood sampling
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.